FGF4 and breast cancer: Mice cohorts with size-matched EF43.fgf4 mammary tumors received a single systemic iv administration of targeted CSSTRESAC-AAVP-HSVtk (5 × 1010 TU) or control fd-AAVP-HSVtk.